Akebia Therapeutics (AKBA) Stock Price, Quote & News

Company Profile

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 617 871 2098

Fax: 617 871 2099

Website: www.akebia.com

Address:

245 First Street, Suite 1400, Cambridge, United States

buckeye1979 May. 14 at 2:36 AM

$AKBA I appreciate the transparency that you are shorting. Helps put your wise advice in perspective.

3 · Reply

Flamegrilled May. 14 at 2:31 AM

$AKBA all bullish posts are garbage. facts. this company has good product but also has an incompetent leader and or leadership. that said sell on the next fake pump and move on.

1 · Reply

MB76 May. 14 at 2:25 AM

$AKBA Notice since ER volume is approx. double what it had been for the past 3 months, HMMM!!!!!!!!!!!! WE SEE YOU!!!!!!!!!!!!!

1 · Reply

MB76 May. 14 at 2:23 AM

$AKBA Look at the DP volume and look at how low the DP short % is. Either they are covering which I doubt, or they are buying shares via DP and then selling them via exchange to drive the price back down. This allows the price to stay down without showing a short sale. The shares are being acquired via DP so the price isn't affected by the buys yet the sales put downward pressure on the price because they are done on the exchange. TYPICAL SP MANIPULATION!!! Again, more GAMES!!!!!!!!!!!!!!!!!

0 · Reply

Mr_Pithy May. 14 at 12:50 AM

$AKBA Nasdaq/com - Comparison of May 13, 2026 to August 8, 2025. Institutional ownership is up, 47.54% (05-13-26), 38.67% (08-08-25). Total institutional holders are up 209 (05-13-26), 163 (08-08-25). Total held positions up, 76,112,318 (05-13-26), 63,755,958 (08-08-25). Total increased/held positions up, 106,748,265 (05-13-26), 97,964,082 (08-08-25). Total institutional shares up, 127,538,808 (05-13-26), 101,568,025 (08-08-25). 05-13-26 data below. 08-08-25 inside post. Good luck ☘️ to all of us.

3 · Reply

Noname2022 May. 14 at 12:32 AM

$AKBA

0 · Reply

MB76 May. 13 at 11:31 PM

$AKBA Either they are covering big time or they are continuing to play massive GAMES!!

1 · Reply

purotango May. 13 at 10:15 PM

$AKBA JB: "What a deal for another 150,000,000 hamburgers!"

0 · Reply

dontbuytrash May. 13 at 9:53 PM

$AKBA this what I sent to Mercedes and John Butler and their investor relations. I doubt they will respond but I have to give them my two cents

4 · Reply

I_Eat_Crayons May. 13 at 9:43 PM

$AKBA Midweek reminder

0 · Reply

Akebia Therapeutics Earnings Call Transcript: Q1 2026

May 7, 2026, 7:00 AM EDT - 6 days ago

Akebia Therapeutics Reports First Quarter 2026 Financial Results and Commercial and Pipeline Highlights

May 4, 2026, 4:05 PM EDT - 9 days ago

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 4, 2026, 8:00 AM EDT - 9 days ago

Akebia Therapeutics Announces Vadadustat Post-hoc Win Statistics Analysis Demonstrating Statistically Significant Reduction in Mortality and Hospitalization Composite Endpoint Published in the Journal of American Society of Nephrology

Apr 30, 2026, 4:05 PM EDT - 13 days ago

Akebia Therapeutics to Report First Quarter 2026 Financial Results and Discuss Recent Business Highlights

2026-04-13T12:52:17.000Z - 4 weeks ago

Akebia doses first participants in AKB-9090 trial

Apr 13, 2026, 8:00 AM EDT - 4 weeks ago

Akebia Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of AKB-9090

Apr 7, 2026, 8:00 AM EDT - 5 weeks ago

Akebia Therapeutics to Conduct Investor Meetings at the Raymond James 2026 Biotech Innovation Symposium

Apr 2, 2026, 10:00 AM EDT - 5 weeks ago

Akebia Therapeutics Transcript: R&D Day 2026

Apr 1, 2026, 4:05 PM EDT - 6 weeks ago

Akebia Therapeutics Appoints Biopharmaceutical Leader Philip Vickers, Ph.D. to its Board of Directors

Mar 19, 2026, 4:05 PM EDT - 7 weeks ago

Akebia Therapeutics to Host Virtual R&D Day Highlighting Robust Kidney Disease Pipeline, on April 2, 2026

Mar 9, 2026, 8:00 AM EDT - 2 months ago

Akebia Therapeutics Transcript: Leerink Global Healthcare Conference 2026

Mar 3, 2026, 8:00 AM EST - 2 months ago

Akebia Therapeutics to Present at the Leerink Partners 2026 Global Healthcare Conference

Feb 26, 2026, 8:00 AM EST - 2 months ago

Akebia Therapeutics Earnings Call Transcript: Q4 2025

Feb 26, 2026, 7:00 AM EST - 2 months ago

Akebia Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial and Pipeline Highlights

2026-02-25T12:25:29.000Z - 2 months ago

Akebia price target lowered to $4 from $5 at BTIG

Feb 19, 2026, 8:00 AM EST - 2 months ago

Akebia Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Discuss Recent Business Highlights

Feb 12, 2026, 9:30 AM EST - 3 months ago

Akebia Therapeutics Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

2026-02-06T11:56:25.000Z - 3 months ago

Akebia price target lowered to $4 from $6 at Piper Sandler

Feb 4, 2026, 8:00 AM EST - 3 months ago

Akebia Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026

2026-01-12T13:52:21.000Z - 4 months ago

Akebia announces corporate updates, 2026 pipeline outlook

Jan 12, 2026, 8:00 AM EST - 4 months ago

Akebia Therapeutics Announces Corporate Updates and 2026 Pipeline Outlook

2026-01-06T13:22:48.000Z - 4 months ago

Akebia announces first patient dosed in Phase 2 trial of praliciguat

Jan 6, 2026, 8:00 AM EST - 4 months ago

Akebia Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of Praliciguat for the Treatment of Focal Segmental Glomerulosclerosis (FSGS)

Dec 2, 2025, 4:30 PM EST - 5 months ago

Akebia Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference

2025-12-01T12:21:08.000Z - 5 months ago

Akebia Therapeutics announces establishment of rare kidney disease pipeline

QTTB

2025-12-01T12:11:17.000Z - 5 months ago

Q32 Bio sells complement inhibitor ADX-097 to Akebia for $12M upfront

QTTB

2025-12-01T12:05:21.000Z - 5 months ago

Q32 Bio sells complement inhibitor ADX-097 to Akebia

QTTB

Dec 1, 2025, 7:00 AM EST - 5 months ago

Akebia Announces Establishment of Rare Kidney Disease Pipeline

Dec 1, 2025, 7:00 AM EST - 5 months ago

Q32 Bio Sells Complement Inhibitor ADX-097

QTTB

Nov 24, 2025, 8:00 AM EST - 6 months ago

Akebia Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference

Nov 17, 2025, 7:00 AM EST - 6 months ago

Akebia Therapeutics Transcript: Jefferies London Healthcare Conference 2025

Nov 10, 2025, 3:00 PM EST - 6 months ago

Akebia Therapeutics Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 10, 2025, 8:00 AM EST - 6 months ago

Akebia Therapeutics Earnings Call Transcript: Q3 2025

Nov 10, 2025, 7:00 AM EST - 6 months ago

Akebia Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Nov 6, 2025, 6:30 PM EST - 6 months ago

Vafseo® (vadadustat) Dialysis Dependent Patient Post Hoc Data Analysis: Composite of All-Cause Mortality and Hospitalization Outcomes Statistically More Favorable for Patients Receiving Vadadustat vs. ESAs

Nov 4, 2025, 8:00 AM EST - 6 months ago

Akebia Therapeutics to Present at Upcoming Investor Conferences

Oct 30, 2025, 8:00 AM EDT - 6 months ago

Akebia Therapeutics to Report Third Quarter 2025 Financial Results and Discuss Recent Business Highlights

2025-10-30T10:11:16.000Z - 6 months ago

Akebia price target lowered to $6 from $8 at H.C. Wainwright

2025-10-28T20:45:13.000Z - 7 months ago

Akebia says not in alignment with FDA on path forward for VALOR clinical trial

Oct 28, 2025, 4:30 PM EDT - 7 months ago

Akebia Therapeutics Provides Update on Vafseo for Non-Dialysis Patients

Oct 20, 2025, 8:08 AM EDT - 7 months ago

Akebia Therapeutics Announces Five Presentations at ASN Kidney Week 2025

Sep 8, 2025, 12:00 PM EDT - 8 months ago

Akebia Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 4, 2025, 8:00 AM EDT - 8 months ago

Akebia Therapeutics Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Sep 2, 2025, 4:05 PM EDT - 9 months ago

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2025-08-21T12:21:04.000Z - 9 months ago

Akebia, IRC announce broad availability of Vafseo across IRC dialysis clinics

Aug 21, 2025, 8:00 AM EDT - 9 months ago

Akebia Therapeutics and Innovative Renal Care Announce Nationwide Availability of Vafseo® (vadadustat) Across All IRC Dialysis Clinics

Aug 13, 2025, 1:30 PM EDT - 9 months ago

Akebia Therapeutics Transcript: Canaccord Genuity’s 45th Annual Growth Conference

Aug 7, 2025, 8:00 AM EDT - 9 months ago

Akebia Therapeutics Earnings Call Transcript: Q2 2025

Aug 7, 2025, 7:00 AM EDT - 9 months ago

Akebia Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Aug 6, 2025, 8:00 AM EDT - 10 months ago

Akebia Therapeutics to Present at Canaccord Genuity's 45th Annual Growth Conference

2025-08-04T12:15:36.000Z - 10 months ago

Akebia initiates post-marketing study to identify benefits of Vafseo

Aug 4, 2025, 8:00 AM EDT - 10 months ago

Akebia Initiates Vafseo® (vadadustat) Post-Marketing Study in Conjunction with Large Dialysis Organization

Jul 31, 2025, 8:00 AM EDT - 10 months ago

Akebia Therapeutics to Report Second Quarter 2025 Financial Results and Discuss Recent Business Highlights

Jul 14, 2025, 10:00 AM EDT - 10 months ago

Akebia Therapeutics Transcript: H.C. Wainwright 4th Annual Kidney Virtual Conference

Jul 8, 2025, 8:00 AM EDT - 11 months ago

Akebia Therapeutics to Present at the H.C. Wainwright 4th Annual Kidney Virtual Conference

Jun 5, 2025, 8:45 AM EDT - 1 year ago

Akebia Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

2025-06-04T12:05:24.000Z - 1 year ago

Akebia announces JASN published analysis from vadadustat phase 3 program

Jun 4, 2025, 8:00 AM EDT - 1 year ago

Vadadustat U.S. Patient Data from Global Phase 3 Clinical Program Published in Journal of the American Society of Nephrology

2025-06-04T10:15:38.000Z - 1 year ago

Akebia assumed with a Buy at H.C. Wainwright

May 28, 2025, 8:00 AM EDT - 1 year ago

Akebia Therapeutics to Present at the Jefferies Global Healthcare Conference 2025

May 27, 2025, 8:00 AM EDT - 1 year ago

Akebia Therapeutics Announces Three Poster Presentations at the European Renal Association Congress 2025

May 20, 2025, 2:30 PM EDT - 1 year ago

Akebia Therapeutics Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

May 13, 2025, 8:00 AM EDT - 1 year ago

Akebia Therapeutics to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference

May 8, 2025, 8:00 AM EDT - 1 year ago

Akebia Therapeutics Earnings Call Transcript: Q1 2025

May 8, 2025, 7:00 AM EDT - 1 year ago

Akebia Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 1, 2025, 8:00 AM EDT - 1 year ago

Akebia Therapeutics to Report First Quarter 2025 Financial Results and Discuss Recent Business Highlights

Apr 3, 2025, 8:00 AM EDT - 1 year ago

Akebia Therapeutics Announces Positive Opinion of European Medicines Agency for XOANACYL®, an Oral Therapy for Chronic Kidney Disease Licensed to Averoa

Mar 25, 2025, 8:00 AM EDT - 1 year ago

Akebia Therapeutics Announces Poster Presentations at NKF Spring Clinical Meetings 2025

Mar 19, 2025, 10:17 PM EDT - 1 year ago

Akebia Therapeutics Announces Pricing of Public Offering of Common Stock

Mar 19, 2025, 4:01 PM EDT - 1 year ago

Akebia Therapeutics Announces Proposed Public Offering of Common Stock

Mar 13, 2025, 8:00 AM EDT - 1 year ago

Akebia Therapeutics Earnings Call Transcript: Q4 2024

Mar 13, 2025, 7:00 AM EDT - 1 year ago

Akebia Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Vafseo® (vadadustat) Commercial Launch Progress Update

Mar 6, 2025, 8:00 AM EST - 1 year ago

Akebia Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Discuss Recent Business Highlights

Jan 16, 2025, 10:30 AM EST - 1 year ago

Akebia Therapeutics Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 13, 2025, 8:00 AM EST - 1 year ago

Akebia Therapeutics Announces Multiple Positive Business Updates

Dec 18, 2024, 8:00 AM EST - 1 year ago

Akebia Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 3, 2024, 10:30 AM EST - 1 year ago

Akebia Therapeutics Transcript: Piper Sandler 36th Annual Healthcare Conference

Dec 3, 2024, 7:00 AM EST - 1 year ago

U.S. Renal Care Enrolled First Patients in the VOICE Collaborative Clinical Trial of Vafseo® (vadadustat) for CKD Patients on Dialysis

Nov 25, 2024, 8:00 AM EST - 1 year ago

Akebia Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference

Nov 21, 2024, 8:00 AM EST - 1 year ago

Akebia Therapeutics Transcript: Jefferies London Healthcare Conference 2024

Nov 14, 2024, 8:00 AM EST - 1 year ago

Vadadustat Alternative Dosing Study Results Published in the American Journal of Kidney Disease

Nov 12, 2024, 8:00 AM EST - 1 year ago

Akebia Therapeutics to Present at the Jefferies London Healthcare Conference

Nov 7, 2024, 8:00 AM EST - 1 year ago

Akebia Therapeutics Earnings Call Transcript: Q3 2024

Nov 7, 2024, 7:00 AM EST - 1 year ago

Akebia Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Nov 1, 2024, 8:00 AM EDT - 1 year ago

Akebia Therapeutics to Report Third Quarter 2024 Financial Results and Discuss Recent Business Highlights

buckeye1979 May. 14 at 2:36 AM

$AKBA I appreciate the transparency that you are shorting. Helps put your wise advice in perspective.

3 · Reply

Flamegrilled May. 14 at 2:31 AM

$AKBA all bullish posts are garbage. facts. this company has good product but also has an incompetent leader and or leadership. that said sell on the next fake pump and move on.

1 · Reply

MB76 May. 14 at 2:25 AM

$AKBA Notice since ER volume is approx. double what it had been for the past 3 months, HMMM!!!!!!!!!!!! WE SEE YOU!!!!!!!!!!!!!

1 · Reply

MB76 May. 14 at 2:23 AM

0 · Reply

Mr_Pithy May. 14 at 12:50 AM

3 · Reply

Noname2022 May. 14 at 12:32 AM

$AKBA

0 · Reply

MB76 May. 13 at 11:31 PM

$AKBA Either they are covering big time or they are continuing to play massive GAMES!!

1 · Reply

purotango May. 13 at 10:15 PM

$AKBA JB: "What a deal for another 150,000,000 hamburgers!"

0 · Reply

dontbuytrash May. 13 at 9:53 PM

$AKBA this what I sent to Mercedes and John Butler and their investor relations. I doubt they will respond but I have to give them my two cents

4 · Reply

I_Eat_Crayons May. 13 at 9:43 PM

$AKBA Midweek reminder

0 · Reply

Mr_Pithy May. 13 at 8:49 PM

$AKBA “The FDA is opening a public docket to solicit input & comments on FDA’s efforts w/ respect to drug repurposing to address unmet medical needs. FDA is requesting info. on potential priority disease areas & potential candidates for drug repurposing w/ focus on FDA approved drugs for which there appears to be no commercial interest in adding a new use thru a supplement to a new drug application. Info. provided thru this public docket will help the Agency refine our efforts toward considering & evaluating candidates for drug repurposing. ANALYSIS: (1)Drug repurposing from Vafseo DD to Vafseo NDD; (2)Unmet medical needs - Anemia assoc. w/ Chronic Kidney Disease NDD, Covid-19, ARDS; (3)Priority disease areas - anemia, chronic kidney disease, Covid-19, ARDS; (4)Focus on FDA approved drug - Vafseo DD; (5)No commercial interest - as opposed to medical interest - in adding new use thru NDA; (6)Candidate for drug repurposing - Vafseo DD to Vafseo NDD. Good luck 🍀 to honest investors.

4 · Reply

Mr_Pithy May. 13 at 8:19 PM

$AKBA May 12th, close $1.1800. 4,573,600 shares traded. May 13th, close $1.1800. 3,663,131 shares traded. Total shares traded 8,236,731. No stock price rise, no stock price drop, no stock price manipulation. Good luck 🍀, we need it.

1 · Reply

seandallas May. 13 at 8:13 PM

$AKBA * credit to @DonnyDonowitz

0 · Reply

seandallas May. 13 at 8:02 PM

$AKBA

0 · Reply

Noname2022 May. 13 at 7:09 PM

$AKBA $CRMD https://www.morningstar.com/news/pr-newswire/20260513da57818/us-renal-care-associate-chief-medical-officer-geoffrey-a-block-md-fasn-awarded-2026-aakp-medal-of-excellence-for-lifetime-contributions-to-kidney-care

0 · Reply

jd_76 May. 13 at 7:02 PM

$AKBA TDic must be nice

0 · Reply

jow18 May. 13 at 6:35 PM

$AKBA 2millions shares exchanged and no price movement….hmmm

1 · Reply

KarlDieGlatze May. 13 at 6:28 PM

$AKBA We will NO LONGER be SATISFIED until JOHNNY BOY and his Band of Merry Man Miscreants especially The BOD's are tossed out of this COMPANY!!!!!!!!! They are INCAPABLE quite frankly HANDICAPPED without the ability to manage a GLOBAL FRANCHISE with this drug's capabilities.

0 · Reply

GREENJMB81 May. 13 at 6:16 PM

$AKBA

1 · Reply

FullTrust May. 13 at 6:08 PM

$AKBA i know your birthday you sent me gift got lost in the mail 🎁 I’ll cut you some slack John

1 · Reply

Coach_B1067 May. 13 at 5:52 PM

$AKBA I guess those green bars at the bottom of the chart do not mean anything....smh

1 · Reply

MB76 May. 13 at 5:51 PM

$AKBA This👇clown thinks any of us “actual” investors in AKBA give a sh*t what he thinks or posts!

1 · Reply

Market Cap	316.54M
Revenue (ttm)	236.20M
Net Income (ttm)	-5.35M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	43.12
Profit Margin	-2.27%
Debt to Equity Ratio	1.79

Volume	4,081,100
Avg Vol	2,903,938
Day's Range	N/A - N/A
Shares Out	268.26M
Stochastic %K	13%
Beta	0.35
Analysts	Strong Sell
Price Target	$4.20